RxDoctor Payments Data

Brandon Holbert

Neurology · la Mesa, CANPI 1538695697

Payments from drug & device makers

$1,074in general payments, 2019–2025

Across 17 payments — averaging $63.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neuropace, Inc.$786
  • Eisai Inc.$92
  • Pfizer$54
  • AbbVie$47
  • SK Life Science, Inc.$38
  • Neurelis, Inc.$22
  • plus $35 from 2 others

What the payments were for

  • Travel & lodging$56152%
  • Food & beverage$51448%

General payments by program year

19
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,074 in reported general payments places this provider in the 45th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$87,821
Medicare patients
250
Services billed
1,458

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XcopriCenobamate49$66,277
VimpatLacosamide19$27,116
FycompaPerampanel15$22,456
QuliptaAtogepant15$16,912
Memantine Hcl227$13,689
Emgality PenGalcanezumab-Gnlm14$13,512
Ajovy AutoinjectorFremanezumab-Vfrm18$12,631
Levetiracetam259$10,747
Aimovig AutoinjectorErenumab-Aooe14$10,274
ValtocoDiazepam12$10,030
Lacosamide50$8,299
Carbamazepine ErCarbamazepine23$5,176
Donepezil Hcl282$3,478
Carbidopa-LevodopaCarbidopa/Levodopa93$2,924
Lamotrigine117$2,899

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SK Life Science, Inc.Xcopri$38$66,27749 claims
Eisai Inc.Fycompa$92$22,45615 claims
AbbVieQulipta$47$16,91215 claims
Neurelis, Inc.Valtoco$22$10,03012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,996 neurology providers in California.

Other neurology in la Mesa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →